Adopting ALK and LTK

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 52, 2015, Pages 15783-15784

  Lemke, Greg ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; LEUKOCYTE TYROSINE KINASE; PROTEIN TYROSINE KINASE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; CYTOKINE;

HUMAN; LARGE CELL LYMPHOMA; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; ANIMAL; METABOLISM;

ANIMALS; CYTOKINES; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84952683320     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1521923113     Document Type: Note

References (16)

1. Schlessinger J (2014) Receptor tyrosine kinases: Legacy of the first two decades. Cold Spring Harb Perspect Biol 6(3):a008912.
2. Sharma PS, Sharma R, Tyagi T (2009) Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 15(7):758-776.
3. Shak S; Herceptin Multinational Investigator Study Group (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 26(4, Suppl 12):71-77.
4. Hunter T (2014) The genesis of tyrosine phosphorylation. Cold Spring Harb Perspect Biol 6(5):a020644.
5. Reshetnyak AV, et al. (2015) Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci USA 112:15862-15867.
6. Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13(10):685-700.
7. Morris SW, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151):1281-1284.
8. Iams WT, Lovly CM (2015) Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer. Cancer J 21(5):378-382.
9. Bilsland JG, et al. (2008) Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 33(3):685-700.
10. Lopes SS, et al. (2008) Leukocyte tyrosine kinase functions in pigment cell development. PLoS Genet 4(3):e1000026.
11. Li N, et al. (2004) Gain-of-function polymorphism in mouse and human Ltk: Implications for the pathogenesis of systemic lupus erythematosus. Hum Mol Genet 13(2):171-179.
12. Zhang H, et al. (2014) Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome. Proc Natl Acad Sci USA 111(44):15741-15745.
13. Guan J, et al. (2015) FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma Kinase. eLife, 10.7554/eLife.09811.
14. Murray PB, et al. (2015) Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal 8(360): ra6.
15. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16(2):139-149.
16. Lemke G, Lew ED (2015) A ligand for ALK. Sci Signal 8(360): fs2.